The effect of tiotropium bromide on pulmonary function and inflammatory factors of COPD patients with stable phase / 中国基层医药

ABSTRACT

Objective To explore the improvement of pulmonary function by tiotropium bromide for chronic obstructive pulmonary disease (COPD)patients with stable phase,and to evaluate its effect on inflammatory factors, thus to provide the basis for clinical treatment.Methods 124 COPD patients with stable phase were selected in the hospital from November 2014 to August 2015.According to the admission number with the single and double number, they were randomly divided into the control group and the study group,62 patients in each group.The control group was given conventional treatment,and the study group was given tiotropium on the basis of conventional therapy. Before and after treatment,the forced vital capacity (FVC),forced expiratory volume in one second (FEV1 )and FEV1 /FVC index were assessed in two groups,the serum levels of high -sensitivity C -reactive protein (hs -CRP) and tumor necrosis factor -α(TNF -α)and other inflammatory factors were measured before and after treatment. Results FEV,FEV1 and FEV1 /FVC(%)of the study group after treatment were (1.79 ±0.36)L,(1.24 ±0.29)L and (67.74 ±1.78)% respectively,which were higher than those of the control group [(1.68 ±0.31)L,(1.03 ± 0.25)L and (62.91 ±1.84)%],the differences were statistically significant (t =9.64,9.28,9.60,all P <0.05). The serum levels of hs -CRP and TNF -αof the study group after treatment were (6.10 ±0.38)mg/L and (6.12 ±0.42)ng/ml,which were lower than those of the control group [(1.54 ±0.09)g/L,(8.29 ±0.31 )ng/mL],the differences were statistically significant (t =12.51,9.24,all P <0.05 ).Conclusion Application of tiotropium bromide for the stable COPD patients can significantly improve the patients'lung function,lower levels of inflammatory factors.And it has positive clinical significance in stable condition,slow disease progression.